Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer

Inclusion Criteria: * histologically documented prostate cancer confirmed by a pathology report from prostate biopsy or radical prostatectomy specimen * metastatic status as evidenced by imaging obtained \</= 56 days prior to registration demonstrating bone metastasis or lymph node metastasis * castrate resistant prostate cancer: castrate levels of testosterone (\</= 50 ng/dL); evidence of disease progression concomitant with surgical or medical castration * serum PSA \>/= 2.0 ng/mL * castrate levels of testosterone (\</= 50 ng/dL) achieved via medical or surgical castration * baseline Eastern Cooperative Oncology Group (ECOG) performance status of \</= 1 * systolic blood pressure (BP) \</= 140 mm Hg and diastolic BP \</= 90 mm Hg at screening * adequate baseline hematologic, renal, and liver functions * must live in a permanent residence within a comfortable driving distance (round trip within one day) of the clinical trial site Exclusion Criteria: * the presence of known lung, liver, or brain metastases, malignant pleural effusions, or malignant ascites * New York Heart Association Class III or IV heart failure * any medical condition that may be compromised by increases in blood pressure, hypokalemia, or fluid retention * Child-Pugh Class B or C hepatic insufficiency * spinal cord compression, imminent long bone fracture, or any other condition likely to require radiation therapy and/or steroids for pain control * known adrenalcortical insufficiency * any medical contra…